Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?

Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?

IntroductionThe European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) announced conditions for using recombinant human interleukin-1 receptor antagonist (rhIL-1ra) to treat hospitalized patients with Coronavirus disease 2019 (COVID-19) and risk for progression. The...

Full description

Bibliographic Details
Main Authors: Leland Shapiro, Sias Scherger, Carlos Franco-Paredes, Amal Gharamti, Andrés F. Henao-Martinez
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Microbiology
Subjects:
anakinra
COVID-19
sepsis
cytokines
cytokine storm
inflammation
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2023.1250483/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2023.1250483/full

Similar Items